The safety of vedolizumab for the treatment of ulcerative colitis

References

• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
   PubMed Web of Science ®Google Scholar
• Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:942–951.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30.
   PubMed Web of Science ®Google Scholar
• McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883–898.
   PubMed Web of Science ®Google Scholar
• Bravata I, Allocca M, Fiorino G, et al. Integrins and adhesion molecules as targets to treat inflammatory bowel disease. Curr Opin Pharmacol. 2015;25:67–71.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–1683.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–1925.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Rare neurological condition linked to newer monoclonal antibody biologics. Jama. 2009;301:1423–1424.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361:1067–1074.
   PubMed Web of Science ®Google Scholar
• Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol. 2012;12:25–35.
   PubMedGoogle Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.
   PubMed Web of Science ®Google Scholar
• Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97–110.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64:77–83.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499–2507.
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18:1470–1479.
   PubMed Web of Science ®Google Scholar
• Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151–1159.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2016 Oct 7. Epub ahead of print.doi:10.1136/gutjnl-2016-312293.
   PubMedGoogle Scholar
• Takeda. An efficacy and safety study of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) in participants with ulcerative colitis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2016 Oct 20]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02497469. NLM Identifier: NCT02497469.
   Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035–1058.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Gionchetti P, Daperno M, et al. Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis. 2016;48:360–370.
   PubMedGoogle Scholar
• Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. Gastroenterology. 2015;149:238–245.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090–1102.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:1593–1601.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis. 2015;21:2879–2885.
   PubMed Web of Science ®Google Scholar
• Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2015;14:1473–1479.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016 Feb 18; pii: gutjnl-2015-311079. [ Epub ahead of print]. DOI:10.1136/gutjnl-2015-311079
   Google Scholar
• Wang MC, Zhang LY, Han W, et al. PRISMA–efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93:e326.
   PubMed Web of Science ®Google Scholar
• Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther. 2017 Jan 9. Epub ahead of print.doi:10.1007/s12325-016-0467-6.
   PubMedGoogle Scholar
• Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis. 2016;10:402–409.
   PubMed Web of Science ®Google Scholar
• Wyant T, Estevam J, Yang L, et al. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom. 2016;90:168–176.
   PubMed Web of Science ®Google Scholar
• Rosario M FI, Milch C, et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2. Inflamm Bowel Dis. 2013;19(suppl 1):P140.
   Google Scholar
• Mocko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of ulcerative colitis: A systematic review and network meta-analysis. Pharmacotherapy. 2016;36:870–879.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2016 Sep 28;jjw177. [ Epub ahead of print].
   Google Scholar
• Strik AS, Bots SJ, D’Haens G, et al. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Rev Clin Pharmacol. 2016;9:429–439.
   PubMed Web of Science ®Google Scholar